secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2023-06-07T23:59:59+00:00
Accession:  0001628280-23-021318
Event type: regulatory
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland Pharmaceuticals receives FDA waiver, $1.2M refund for RediTrex fees
------------------------------------------------------------------------------

- FDA granted barrier-to-innovation waiver based on ifetroban clinical programs addressing unmet medical needs.
- Company will receive refund of approximately $1.2 million in prescription drug program fees for RediTrex.
- Refund expected within 45 days from FDA's Office of Financial Management.
- Waiver follows Cumberland's April 3, 2023 request for reconsideration through counsel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000162828023021318/0001628280-23-021318-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000162828023021318/cpix-20230602.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-021318

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer